Close

Agile Therapeutics (AGRX): Phase 3 Pearl Index High but Explainable - Janney

January 4, 2017 7:04 AM EST Send to a Friend
Janney Montgomery Scott analyst, Ken Trbovich, reiterated his Buy rating on shares of Agile Therapeutics (NASDAQ: AGRX) after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login